DreaMed Diabetes’ innovative AI platform is now available at leading children’s US hospital thanks to a new agreement
- DreaMed, an Israeli biotech startup, has developed artificial intelligence (AI) that has the potential to change how diabetes is handled in the healthcare business.
- DreaMed AI platform provides economic advantages.
- Diabetes affects an estimated 463 million people globally, according to the World Health Organization.
Recent research by the U.S Department of Health and Human Services has revealed that overall, 34.2 million individuals of all ages in the United States suffered from diabetes, accounting for 10.5 percent of the population. Diabetes affected 34.1 million adults aged 18 and over, or 13.0% of all adults in the United States.
With the diabetes statistics in the United States being so high, many medical companies have been continuously innovating ways to lessen the statistics. The World Health Organization states that an estimate of 463 million people worldwide are living with diabetes. In the United States alone, the ratio of endocrinologists per caseload is one to 41,000; a ratio that results in medical mismanagement in more than half of all diabetes cases. DreaMed, an Israeli biotech start-up founded in 2014 to address the lack of access, has positioned itself at the vanguard of altering how diabetes is handled across the healthcare industry. For millions of patients who do not have access to endocrinologists or diabetes-related medical personnel, DreaMed Diabetes AI is monitoring and treating diabetes. The FDA-approved Advisor Pro is now being used in a top American children’s hospital.
Doing Sufficient Research
DreaMed has focused the Advisor Pro’s capabilities towards Type 1 diabetic patients during the last two years, beginning with the FDA’s first approval of the product in 2018. The unique medical equipment was recently expanded to assess and prescribe treatments for Type 2 diabetic patients, according to recent discoveries and specific advancements by the company’s scientific team. Unlike any other vendor in the diabetes digital healthcare industry, DreaMed Advisor is based on 10 years of clinically tested data from hundreds of diabetic patients, as well as artificial intelligence (AI) technology. This groundbreaking application might save the lives of millions of diabetics, according to the World Health Organization (WHO), who suffer from one of the most common chronic diseases on the planet.
What Sets DreMeds Platform Apart
Because each patient’s diabetic profile and insulin monitoring are so different, optimal diabetes management necessitates a highly tailored treatment plan and monitoring. Data from a patient’s CGM, SMBG, and insulin pump is saved on DreaMed’s platform. The DreaMed Advisor Pro was just approved by the FDA in the United States. Since then, he has been experimenting with digital and online technology in the hopes of improving the lives of patients all around the world. This technology might be described as a diabetes data adviser and decision-support tool for real-time and individualized therapy. This sort of artificial intelligence incorporates real-world expertise and has the ability to handle appropriate treatment alternatives swiftly and automatically in order to maintain balanced glucose levels.
The MD Logic-based algorithm, which was developed by top doctors and endocrinologists, is then used to organize the data. As a result, the Advisor Pro creates a therapy plan that may be used to streamline the patient and provider monitoring process. The Advisor Pro not only improves patient quality of life, but it also lowers clinical visit administrative costs, which are estimated to be in the billions of dollars per year in the United States alone. DreaMed provides hospitals, clinics, patients, and the industry at large with a credible economic advantage due to lower hospitalization expenses as a result of using the Advisor Pro.
Noteworthy Recognition
The company has received substantial recognition and market validation from world-renowned clinical institutions and software companies, including Medtronic Diabetes, DexCom, Yale-New Haven, and Glooko, for its dynamic and comprehensive spectrum of chronic disease AI-based algorithms.
Final Thought
While DreaMed’s recent FDA approval and resulting partnerships placed the company in a key position to possibly improve countless lives, there is still much more ground to cross. Because diabetes is one of the world’s most common diseases, the DreaMed Advisor Pro system faces a number of hurdles in providing a comprehensive, all-encompassing response to a human endoctynologist’s expert advice. According to DreaMed’s CEO, Eran Atlas, the company’s next step is to expand the platform’s capabilities beyond insulin control to include all injectable and oral diabetic drugs.